Key Points
- Vivani director Gregg Williams purchased 1,351,351 shares on Jan. 27 at $1.48 each (~$2.0M), increasing his holdings to 27,915,460 shares (a 5.09% increase) valued at about $41.3M.
- That transaction continues a string of insider buys—Williams also acquired ~1.737M shares each on Nov. 15, Dec. 15 and Jan. 15 at roughly $1.14 per share—signaling sustained insider accumulation.
- For context, Vivani (NASDAQ:VANI) has a market cap of about $108.7M, trades near $1.49 (1‑yr range $0.91–$1.92), is unprofitable (negative EPS) and carries a consensus analyst rating of Hold with a $4.00 target.
Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams purchased 1,351,351 shares of the stock in a transaction dated Tuesday, January 27th. The stock was purchased at an average cost of $1.48 per share, for a total transaction of $1,999,999.48. Following the completion of the acquisition, the director owned 27,915,460 shares of the company's stock, valued at approximately $41,314,880.80. This represents a 5.09% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Gregg Williams also recently made the following trade(s):
- On Thursday, January 15th, Gregg Williams acquired 1,737,765 shares of Vivani Medical stock. The shares were purchased at an average cost of $1.14 per share, with a total value of $1,981,052.10.
- On Monday, December 15th, Gregg Williams bought 1,737,765 shares of Vivani Medical stock. The shares were purchased at an average cost of $1.14 per share, for a total transaction of $1,981,052.10.
- On Saturday, November 15th, Gregg Williams bought 1,737,764 shares of Vivani Medical stock. The stock was purchased at an average price of $1.14 per share, for a total transaction of $1,981,050.96.
Vivani Medical Price Performance
Shares of NASDAQ:VANI opened at $1.49 on Thursday. The firm has a fifty day moving average price of $1.35 and a two-hundred day moving average price of $1.39. The company has a market cap of $108.70 million, a price-to-earnings ratio of -3.31 and a beta of 3.07. Vivani Medical, Inc. has a one year low of $0.91 and a one year high of $1.92.
Vivani Medical (NASDAQ:VANI - Get Free Report) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. Equities research analysts expect that Vivani Medical, Inc. will post -0.41 EPS for the current fiscal year.
Analyst Ratings Changes
VANI has been the topic of several research analyst reports. Zacks Research upgraded shares of Vivani Medical from a "strong sell" rating to a "hold" rating in a research report on Wednesday, November 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Vivani Medical in a report on Friday, January 9th. Finally, Wall Street Zen upgraded shares of Vivani Medical to a "sell" rating in a research report on Saturday, November 22nd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Vivani Medical has a consensus rating of "Hold" and a consensus target price of $4.00.
Read Our Latest Research Report on Vivani Medical
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. Panagora Asset Management Inc. bought a new stake in shares of Vivani Medical in the 2nd quarter worth approximately $25,000. Citadel Advisors LLC bought a new position in shares of Vivani Medical during the 3rd quarter valued at $26,000. Finally, Susquehanna International Group LLP raised its position in Vivani Medical by 100.5% in the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company's stock worth $46,000 after purchasing an additional 16,200 shares during the period. 6.78% of the stock is currently owned by institutional investors.
About Vivani Medical
(
Get Free Report)
Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.
The company's flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
